Rising prevalence of vascular comorbidities in multiple sclerosis: Validation of administrative definitions for diabetes, hypertension, and hyperlipidemia

Multiple Sclerosis Journal

Volumn 18, Issue 9, 2012, Pages 1310-1319

  Marrie, Ruth Ann ^a   Yu, Bo Nancy ^a   Leung, Stella ^a   Elliott, Lawrence ^a   Caetano, Patricia ^a   Warren, Sharon ^b   Wolfson, Christina ^c   Patten, Scott B ^d   Svenson, Lawrence W ^b,d,e   Tremlett, Helen ^f   Fisk, John ^g   Blanchard, James F ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e Surveillance and Assessment   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g DALHOUSIE UNIVERSITY   (Canada)

Author keywords

administrative data; diabetes; hyperlipidemia; hypertension; Multiple sclerosis; prevalence; validation

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GROUPS BY AGE; HOSPITAL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ICD-10; ICD-9-CM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE SCLEROSIS; PHYSICIAN; POPULATION RESEARCH; PRESCRIPTION; PREVALENCE; TREND STUDY; VALIDATION STUDY;

EID: 84865276431     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512437814     Document Type: Article

References (38)

1. Marrie RA, Horwitz RI. Emerging effects of comorbidities on multiple sclerosis. Lancet Neurol. 2010 ; 9: 820-828
2. Marrie RA, Horwitz RI, Cutter G, et al. Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology. 2009 ; 72: 117-124
3. Marrie RA, Cutter G, Tyry T. Substantial adverse association of visual and vascular comorbidities on visual disability in multiple sclerosis. Mult Scler J. 2011 ; 17: 1464-1471
4. Tricco AC, Pham B, Rawson NSB. Manitoba and Saskatchewan administrative health care utilization databases are used differently to answer epidemiologic research questions. J Clin Epidemiol. 2008 ; 61: 192-197
5. Klabunde CN, Warren JL, Legler JM. Assessing comorbidity using claims data: an overview. Med Care. 2002 ; 40: 26-35
6. Klabunde CN, Warren JL, Legler JM. Assessing comorbidity using claims data: An overview. Med. Care. 2002 ; 40 (8 Suppl). 26-35
7. Ottawa, Ontario: Canadian Institute for Health Information ; 2003:
8. Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care. 1998 ; 36: 8-27
9. Winnipeg, Manitoba: Manitoba Health and Healthy Living ; 2008:
10. Marrie RA, Yu N, Blanchard JF, et al. The rising prevalence and changing age distribution of multiple sclerosis in Manitoba. Neurology. 2010 ; 74: 465-471
11. Horton M, Rudick RA, Hara-Cleaver C, et al. Validation of a Self-Report Comorbidity Questionnaire for Multiple Sclerosis. Neuroepidemiology. 2010 ; 35: 83-90
12. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005 ; 58: 840-846
13. Marrie RA, Rudick R, Horwitz R, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology. 2010 ; 74: 1041-1047
14. So L, Evans D, Quan H. ICD-10 coding algorithms for defining comorbidities of acute myocardial infarction. BMC Health Serv Res. 2006 ; 6: 161
15. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005 ; 43: 1130-1139
16. Hux JE, Ivis F, Flintoft V, et al. Diabetes in Ontario: Determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care. 2002 ; 25: 512-516
17. Tu K, Campbell NRC, Chen Z, et al. Accuracy of administrative databases in identifying patients with hypertension. Open Med. 2007 ;: 1
18. Lix L, Yogendran M, Shaw S, et al. Population-based data sources for chronic disease surveillance. Chron Dis Canada. 2008 ; 29: 22-30
19. Blanchard JF, Ludwig S, Wajda A, et al. Incidence and prevalence of diabetes in Manitoba, 1986-1991. Diabetes Care. 1996 ; 19: 807-811
20. Ottawa, Canada: Health Canada ; 2003:
21. Guttmann A, Nakhla M, Henderson M, et al. Validation of a health administrative data algorithm for assessing the epidemiology of diabetes in Canadian children. Pediat Diabetes. 2009 ; 11: 122-128
22. Youden WJ. Index for rating diagnostic tests. Cancer. 1950: 32-35
23. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977 ; 33: 159-174
24. Rothman KJ, Greenland S Modern epidemiology. 2 nd ed.Philadelphia, PA: Lippincott Williams & Wilkins, 1998, p.738. Philadelphia, PA: Lippincott Williams & Wilkins ; 1998: 738.
25. Jacobs LD, Wende KE, Brownscheidle CM, et al. A profile of multiple sclerosis: The New York State Multiple Sclerosis Consortium. Mult Scler. 1999 ; 5: 369-376
26. Rector TS, Wickstrom SL, Shah M, et al. Specificity and sensitivity of claims-based algorithms for identifying members of Medicare+Choice Health Plans that have chronic medical conditions. Health Serv Res. 2004 ; 39: 1839-1858
27. Mark DH. Race and the limits of administrative data. JAMA. 2001 ; 285: 337-338
28. Virnig BA, McBean M. Administrative data for public health surveillance and planning. Ann Rev Public Health. 2001 ; 22: 213-230
29. Bernstein CN, Blanchard JF, Rawsthorne P, et al. Epidemiology of Crohn's Disease and Ulcerative Colitis in a central Canadian Province: A population-based study. Amer J Epidemiol. 1999 ; 149: 916-924
30. Joffres MR, Kamath TV, Williams GR, et al. Impact of guidelines on health care use for the management of dyslipidemia in two Canadian provinces, Alberta and Nova Scotia, from 1990 to 2001. Can J Cardiol. 2004 ; 20: 767-772
31. Brown DW, Anda RF, Felitti VJ. Self-reported information and pharmacy claims were comparable for lipid-lowering medication exposure. J Clin Epidemiol. 2007 ; 60: 525-529
32. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet. 2002 ; 359: 1379-1387
33. Marrie RA, Horwitz R, Cutter G, et al. Comorbidity, socioeconomic status, and multiple sclerosis. Mult Scler. 2008 ; 14: 1091-1098
34. Pohar SL, Jones CA, Warren S, et al. Health status and health care utilization of multiple sclerosis in Canada. Can J Neurolog Sci. 2007 ; 34: 167-174
35. Kang J-H, Chen Y-H, Lin H-C. Comorbidities amongst patients with multiple sclerosis: a population-based controlled study. Eur J Neurol. 2010 ; 17: 1215-1219
36. Rose G. Sick individuals and sick populations. Int J Epidemiol. 1985 ; 14: 32-38
37. Cohen JA. Emerging therapies for relapsing multiple sclerosis. Arch Neurology. 2009 ; 66: 821-828
38. De Coster C, Quan H, Finlayson A, et al. Identifying priorities in methodological research using ICD-9-CM and ICD-10 administrative data: report from an international consortium. BMC Health Serv Res. 2006 ; 6: 77